The anticancer effects of shRNA-targeting AQP3 were observed in experimental NSCLC, further evidenced by the inhibition of AQP3 deletion for lung cancer growth and prolonged survival in preclinnical studies [78]. The gene discussed is AQP3; the disease is lung carcinoma.